Denosumab, a fully human monoclonal IgG~2~ antibody against the receptor activator of nuclear factor-κB ligand, given as a sc at a dose of 60 mg every 6 months increased bone mineral density (BMD) at the lumbar spine and total hip and reduced the incidence of new vertebral, nonvertebral, and hip fractures in predominantly Caucasian postmenopausal women with osteoporosis in the Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study ([@B1]). However, the subgroup analyses did not show significant reduction in the incidence of new vertebral fracture in nonwhites and subjects living in North and Latin America, presumably due to the small number of subjects and/or the low incidence of fracture in these subgroups ([@B2]).

Biannual sc of denosumab 60 mg was selected as an optimum dose in Japanese postmenopausal women with osteoporosis in the dose-response study ([@B3]). The objective of this study was to assess the efficacy of denosumab on fracture risk reduction and safety in Japanese subjects with osteoporosis compared with placebo for 24 months. The exploratory objective was set to consider the clinical positioning of denosumab for the osteoporosis treatment in Japanese patients comparing the data of BMD and bone turnover markers (BTMs) with alendronate 35 mg weekly as the recommended dosage in the prescribing information in Japan. Fracture and safety data were also collected in the alendronate group.

Subjects and Methods
====================

Study design
------------

Denosumab fracture Intervention RandomizEd placebo Controlled Trial (DIRECT) was a randomized, double-blind, placebo-controlled, multicenter trial with an open-label active comparator as a referential arm. Subjects were randomly assigned in a 2:2:1 ratio to receive one of the following three treatments for 24 months: denosumab 60 mg sc every 6 months, placebo for denosumab, or open-label oral alendronate 35 mg weekly. Randomization was stratified by gender. All subjects who received the investigational product (IP) were administered daily supplements containing at least 600 mg calcium and 400 IU vitamin D throughout the study period.

The study was designed by the Steering Committee (T.Nakam., T.Matsu., T.Su., and T.H.) and sponsor (H.T., K.W., and T.O). The sponsor had responsibility for data collection and quality control. The Safety Monitoring Board (T.M., I.G., H.Y., Y.T., S.T., S.M., and T.Y.) met semiannually to monitor subject safety, based on blinded data. Radiographs were assessed by the Central Committee (T.Nakan., M.I., T.So., and M.F.). The oral events reported from the local investigators were reviewed by the dental expert (T.Y.). M.S. oversaw the study conduct. Analyses for publication were the responsibility of the sponsor. The manuscript was contributed to and approved by all authors.

Subjects
--------

Japanese subjects with osteoporosis including postmenopausal women and men aged 50 years or older were eligible for the study if they had one to four prevalent vertebral fractures with a BMD T-score of less than −1.7 (Young Adult Mean in Japan 80%) at the lumbar spine or −1.6 (Young Adult Mean in Japan 80%) at the total hip by dual-energy X-ray absorptiometry based on the diagnostic criteria of primary osteoporosis in Japan ([@B4]). Subjects were excluded if they had more than two moderate and/or any severe vertebral fractures on lateral spine radiographs by semiquantitative (SQ) grading ([@B5]) or if they had evidence of the conditions such as hyperparathyroidism, hypoparathyroidism, hypercalcemia, hypocalcemia, rheumatoid arthritis, or Paget\'s disease of the bone. The subjects were ineligible if they had taken oral bisphosphonates for more than 3 years. Those who had taken bisphosphonates for less than 3 years were eligible if they had received bisphosphonates for less than 2 weeks or had no dosing before 6 months prior to the study enrollment. Subjects were excluded if they had taken selective estrogen receptor modulators, calcitonin, hormone replacement therapy, or teriparatide within 6 weeks before the study enrollment. Additional exclusion criteria included evidence of 2.0 mg/dL or greater serum creatinine, 80 IU/L or greater aspartate aminotransferase, 90 IU/L or greater alanine aminotransferase, or other conditions judged to be inadequate for participation in the study.

The institutional review boards at all study sites approved the protocol and consent process for this study, and all subjects provided written informed consent before participation. This study was conducted in compliance with the ethical principles of the Declaration of Helsinki and in accordance with good clinical practice.

Efficacy endpoints
------------------

The primary endpoint was the 24-month incidence of radiographically determined morphometrical new or worsening vertebral fracture for denosumab vs placebo. The secondary end points included the incidence of new vertebral fracture and nonvertebral fracture; the percentage change from baseline in BMD at the lumbar spine (L1-L4), total hip, femoral neck, and distal one third radius; and the percentage change from baseline in serum concentrations of the BTMs, C-telopeptide of type 1 collagen (CTX-1), and bone-specific alkaline phosphatase (BSAP). The exploratory endpoint included the incidence of major nonvertebral fracture known to be significantly associated with decreased BMD ([@B6]), consisting of the proximal humerus, forearm, ribs/clavicle, pelvis, hip, distal femur, and proximal tibia. The incidence of nonmajor nonvertebral fracture, which included all nonvertebral fracture except for major nonvertebral fracture, was assessed as a post hoc analysis. Fractures of the skull, face, metacarpus, finger, and toe phalanges as well as pathological fractures and those that were associated with severe trauma defined as a fall from a height higher than a stool, chair, or first rung of a ladder or severe trauma other than a fall were excluded ([@B7]).

Efficacy measures
-----------------

Spine radiographs, antero-posterior and lateral, were taken at baseline and every 6 months over 24 months. To identify morphometrical vertebral fracture, the vertebral bodies of the lateral projection from Th4 to L4 were assessed using both the SQ and quantitative morphometry (QM) methods by the experts of the Central Committee who were blinded to treatment as previously reported ([@B4], [@B5]). Both SQ and QM requirements had to be met for prevalent vertebral fractures at baseline. A new vertebral fracture was defined as an increase of at least 1 SQ grading scale in a vertebral body that was normal at baseline and showing loss of height at the anterior, posterior, or central vertebra by at least 20% from baseline. A worsening fracture was defined in the same manner as a new vertebral fracture, with the above criteria applied to a vertebral body with a prevalent fracture. In cases of disagreement between SQ and QM methodologies, a binary SQ assessment was made to adjudicate the discordant results by the committee.

For assessment of nonvertebral fracture, investigators took radiographs at any time during the study to identify the fracture in a subject reporting clinical symptoms. The committee reviewed the radiographs in a blinded manner.

BMD as evaluated by dual-energy X-ray absorptiometry was measured at the above-mentioned four sites at baseline and 3, 6, 12, 18, and 24 months except for the distal one third radius at 3 months. The QDR instrument (Hologic) was used in this study. Quality control and BMD scan analysis were performed centrally (Synarc).

Concentrations of the above two BTMs were measured from fasting serum samples collected in the morning around the same time at baseline and 1, 3, 6, 12, and 24 months before the administration of the IP. Serum CTX-1 and BSAP were evaluated by the central laboratory using an ELISA and chemiluminescent enzyme immunoassay, respectively (Mitsubishi Chemical Medience Corp).

Adverse events (AEs)
--------------------

All subjects were questioned concerning AEs at each visit, and all AEs were assessed, regardless of the determinations of causality by the investigators. The Medical Dictionary for Regulatory Activities (MedDRA, version 14.0) was used to categorize reported AEs. Safety laboratory tests including serum chemistry, hematology, and urinalysis were assessed at baseline and 1, 6, 12, 18, and 24 months. Safety was assessed by recording all AEs, serious AEs, fatal AEs, AEs leading to study discontinuation, and AEs leading to discontinuation of IP. AEs of interests, such as hypocalcemia, bacterial cellulitis, infection, eczema, events potentially related to hypersensitivity, cardiovascular disorder, malignant or unspecified tumors, fracture healing complication, atypical fracture of femur, and osteonecrosis of the jaw (ONJ), were prespecified. A dental expert in this study (T.Y.) reviewed each potential case of ONJ in a blinded manner. Study investigators clinically assessed the healing of nonvertebral fractures within 6 months after their occurrence. Antidenosumab binding antibodies were assessed in those samples of subjects randomized in the denosumab or placebo group.

Statistical analyses
--------------------

This study had 90% power to detect a 50% reduction in new or worsening vertebral fracture in the denosumab group as compared with the placebo group, assuming a 16% incidence in the placebo group at 24 months and 20% subject discontinuation rate. The study was planned to enroll 440 subjects per double-blind treatment group (denosumab or placebo). The number of subjects for the alendronate group was set to be 220. Comparisons for alendronate vs. denosumab or placebo were post hoc analyses and not prespecified in the protocol.

Efficacy analyses were performed using the full analysis set, which includes all randomized subjects except for those who did not have osteoporosis at screening, did not receive the IP or had no available efficacy data after the first dose of the IP. All tests were performed at a two-sided 5% significant level, and all confidence intervals (CIs) are given as two-sided 95% CIs (α = .05).

The 24-month incidence of subjects with new or worsening vertebral, new vertebral, nonvertebral, major nonvertebral, and nonmajor nonvertebral fracture was estimated by the Kaplan-Meier method with 95% CIs. A log-rank test was used to compare the incidence between the denosumab and placebo groups. A proportional hazard model was used to estimate the hazard ratios (HRs). The grouped survival data approach ([@B8]) was applied to the log-rank test and the estimation of the HR for the statistical analysis of vertebral fracture because most vertebral fractures were observed at the scheduled visits. The subgroup analyses in the women and men were conducted for new or worsening vertebral fracture and new vertebral fracture.

A Student\'s *t* test was used to compare the percentage changes from baseline in BMD between the denosumab and placebo groups. The Wilcoxon rank-sum test was used to compare the percentage changes from baseline in the BTMs between the denosumab and placebo groups.

The safety analysis set included all subjects who received at least one dose of IP, and AEs were summarized by the randomized treatment groups.

For the exploratory objective, the referential comparisons for the alendronate vs the denosumab or placebo group were conducted for fractures, BMD and BTMs using the same method as mentioned above.

Results
=======

Subjects
--------

A total of 1262 subjects were randomized at 119 study sites, 500, 511, and 251 in the denosumab, placebo, and alendronate groups, respectively ([Figure 1](#F1){ref-type="fig"}). The numbers of subjects who completed the study at 24 months were 414 (82.8%), 416 (81.4%), and 204 (81.3%), respectively.

![Disposition of study subjects. \*, Three subjects were excluded due to lack of efficacy data after IP administration; \*\*, one subject was excluded due to lack of efficacy data after IP administration. FAS, full analysis set.](zeg9991407920001){#F1}

Baseline characteristics of the subjects were similar across the three groups ([Table 1](#T1){ref-type="table"}). The proportion of subjects with at least one vertebral fracture at baseline was 98.3%. The mean BMD T-score at the lumbar spine, total hip, and femoral neck was −2.74, −1.98 and −2.32, respectively.

###### 

Baseline Characteristics of the Subjects

                                                                       Double Blind        Open Label          
  -------------------------------------------------------------------- ------------------- ------------------- -------------------
  Gender, n, %                                                                                                 
      Female                                                           449 (95.1)          456 (95.0)          230 (95.0)
      Male                                                             23 (4.9)            24 (5.0)            12 (5.0)
  Age, y                                                                                                       
      Mean-year^[a](#TF1-1){ref-type="table-fn"}^                      69.9 ± 7.36         69.0 ± 7.67         70.2 ± 7.31
      Group, n, %                                                                                              
          \<65                                                         99 (21.0)           126 (26.3)          56 (23.1)
          65--74                                                       246 (52.1)          231 (48.1)          112 (46.3)
          ≥75                                                          127 (26.9)          123 (25.6)          74 (30.6)
  Body mass index, kg/m^2a^                                            22.6 ± 2.9          22.4 ± 3.1          22.3 ± 3.0
  Prevalent vertebral fractures, n, %                                                                          
      0                                                                6 (1.3)             9 (1.9)             5 (2.1)
      1                                                                315 (66.7)          319 (66.5)          157 (64.9)
      2                                                                113 (23.9)          105 (21.9)          62 (25.6)
      ≥3                                                               38 (8.1)            47 (9.8)            18 (7.4)
  T-score^[a](#TF1-1){ref-type="table-fn"}^                                                                    
      Lumbar spine (L1-L4)                                             −2.78 ± 0.89        −2.73 ± 0.88        −2.69 ± 0.94
      Total hip                                                        −2.01 ± 0.79        −1.95 ± 0.73        −1.96 ± 0.79
      Femoral neck                                                     −2.38 ± 0.70        −2.29 ± 0.71        −2.29 ± 0.69
  Serum CTX-1, ng/mL^[b](#TF1-2){ref-type="table-fn"}^                 0.64 (0.44, 0.78)   0.63 (0.43, 0.78)   0.61 (0.42, 0.77)
  Serum 25-hydroxyvitamin D, ng/mL^[a](#TF1-1){ref-type="table-fn"}^   20.97 ± 6.08        20.63 ± 5.91        21.10 ± 6.30

Twenty subjects were originally assessed as having one or more vertebral fractures during an initial single reviewer assessment, and subsequent blinded adjudication by the committee determined that no prevalent vertebral fracture was present at baseline. Subjects were excluded if they had less than 12 ng/mL serum 25-hydroxyvitamin D concentration at screening.

Data are mean ± SD.

Data are mean (quartiles 1 and 3).

Consequently, five subjects (two, one, and two in the denosumab, placebo, and alendronate groups, respectively) were not classified as osteoporosis based on the diagnostic criteria in Japan.

Fractures
---------

The 24-month incidence of new or worsening vertebral fracture was 3.6% in the denosumab group and 10.3% in the placebo group, with the reduction in risk by 65.7% (*P* = .0001) ([Figure 2](#F2){ref-type="fig"}A and [Supplemental Table 1](http://press.endocrine.org/doi/suppl/10.1210/jc.2013-4175/suppl_file/jc-13-4175.pdf)). In the subgroup analysis in women, the risk of new or worsening vertebral fracture at 24 months was reduced by 63.2% in the denosumab group compared with the placebo group (HR 0.368, 95% CI 0.207--0.653, *P* = .0004). The 24-month incidence of new vertebral fracture was 2.2% in the denosumab group and 8.6% in the placebo group, with the reduction in risk by 74.0% (*P* \< .0001) ([Figure 2](#F2){ref-type="fig"}B). In the subgroup analysis in women, the risk of new vertebral fracture at 24 months was reduced by 72.6% in the denosumab group compared with the placebo group (HR 0.274, 95% CI 0.136--0.553, *P* = .0001).

![Cumulative incidence of vertebral fracture. The cumulative incidence of new or worsening vertebral fracture (A) and new vertebral fracture (B) in all subjects in the denosumab and placebo groups. For panels A and B, the percentages given were incidence by the Kaplan-Meier estimate over a 24-month treatment period. The HR (95% CI) and *P* value of new or worsening vertebral fracture (A) for the denosumab vs the placebo group was 0.343 (0.194, 0.606) and *P* = .0001. The HR (95% CI) and *P* value of a new vertebral fracture (B) for the denosumab vs placebo group was 0.260 (0.129, 0.521) and *P* \< .0001. In the subgroup analysis in men at 24 months, the incidence of new or worsening vertebral fracture in the denosumab and placebo groups was 0% and 12.5%, respectively, and that of new vertebral fracture in the denosumab and placebo groups was 0% and 8.3%, respectively. The *P* value of a new or worsening vertebral fracture and new vertebral fracture for the denosumab vs placebo group was *P* = .0748 and *P* = .1478, respectively. The HRs (95% CI) were not estimated because there were no subjects with a vertebral fracture in the denosumab group.](zeg9991407920002){#F2}

The 24-month incidence of nonvertebral fracture was 4.1% in both the denosumab and placebo groups (*P* = .9951). The 24-month incidence of major nonvertebral fracture was 1.6% and 3.7% in the denosumab and placebo groups, respectively (*P* = .0577). The 24-month incidence of nonmajor nonvertebral fracture was 2.5% and 0.4% in the denosumab and placebo groups, respectively (*P* = .0120).

In the alendronate group, the 24-month incidence of new or worsening vertebral, new vertebral, nonvertebral, major nonvertebral, and nonmajor nonvertebral fracture was 7.2%, 5.1%, 2.7%, 2.3%, and 0.4%, respectively. As the referential comparison, the HR (95% CI) and the *P* value of new vertebral fracture for the alendronate vs placebo group was 0.641 (0.335, 1.226) and *P* = .1749, and for the denosumab vs alendronate group was 0.416 (0.180, 0.962) and *P* = .0344.

Bone mineral density
--------------------

Mean BMD percentage change from baseline at 24 months was 9.1% and 0.1% at the lumbar spine in the denosumab and placebo groups, 4.6% and −1.1% at the total hip, 4.0% and −1.1% at the femoral neck, and 0.5% and −1.8% at distal one third radius, respectively ([Figure 3](#F3){ref-type="fig"}, A--D). The difference between the two groups was significant as early as 3 months at the lumbar spine, total hip, and femoral neck (*P* \< .0001) and 6 months at the distal one third radius (*P* \< .0001).

![Mean BMD percentage changes from baseline. Mean BMD percentage changes from baseline over a 24-month treatment period at the lumbar spine (L1--L4) (A), total hip (B), femoral neck (C), and distal one third radius (D) are shown. a, *P* \< .0001 based on the Student\'s *t* test at each time point for the denosumab vs placebo group; b, a referential comparison, *P* \< .01 based on the Student\'s *t* test at each time point for the alendronate vs placebo group; c, *P* \< .05 based on the Student\'s *t* test at each time point for the denosumab vs alendronate group. The bars show 95% CIs of the mean values at each time point. A central vender performed all BMD analyses. Abnormal vertebrae, such as those with an abnormality, fracture, or artifact, were excluded from analyses.](zeg9991407920003){#F3}

In the alendronate group, the mean BMD percentage change from baseline at 24 months was 7.5%, 3.6%, 2.9%, and −0.2% at the lumbar spine, total hip, femoral neck, and distal one third radius, respectively. As the referential comparison, the difference between the alendronate and placebo groups was significant as early as 3 months at the lumbar spine, total hip, and femoral neck (*P* \< .01) and 6 months at the distal one third radius (*P* \< .01). The difference between the denosumab and alendronate groups was significant as early as 3 months at the lumbar spine and total hip (*P* \< .05), at 12 and 24 months at the femoral neck (*P* \< .05), and from 18 months at the distal one third radius (*P* \< .05).

Bone turnover markers
---------------------

The median percentage change from baseline in serum CTX-1 and BSAP in the denosumab group was reduced by 70.9% at 1 month and 50.2% at 3 months, respectively, and maintained significant reduction levels thereafter ([Figure 4](#F4){ref-type="fig"}, A and B). The difference in serum CTX-1 and BSAP between the denosumab and placebo groups was significant as early as 1 month (*P* \< .0001).

![Median BTM percentage changes from baseline. Median BTM changes from baseline over a 24-month treatment period for serum CTX-1 (A) and serum BSAP (B) are shown. a, *P* \< .0001 based on the Wilcoxon rank-sum test for the denosumab vs placebo group; b, as a referential comparison, *P* \< .01 based on the Wilcoxon rank-sum test at each time point for the alendronate vs placebo group; c, *P* \< .05 based on the Wilcoxon rank-sum test at each time point for the denosumab vs alendronate group. The bars show the interquartile range of the percentage changes from baseline at each time point.](zeg9991407920004){#F4}

In the alendronate group, the median percentage change from baseline in serum CTX-1 and BSAP was reduced by 66.3% and 46.4%, respectively, at 6 months and maintained these reduction levels after 6 months. As the referential comparison, the difference between the alendronate and placebo groups was significant as early as 1 month in serum CTX-1 (*P* \< .01) and as early as 3 months in serum BSAP (*P* \< .05), respectively. The difference in serum CTX-1 and BSAP between the denosumab and alendronate groups was significant as early as 1 month (*P* \< .05), except at 6 months in serum CTX-1.

Safety
------

No differences were found in all AEs, serious AEs, fatal AEs, or AEs leading to discontinuation among the denosumab, placebo and alendronate groups during the first 24 months of the study ([Table 2](#T2){ref-type="table"}). The incidences of AEs of interest and serious AEs including hypocalcemia, bacterial cellulitis, infection, eczema, malignant or unspecified tumors, hypersensitivity, or cardiovascular disorder were not different among the groups. The most frequent infections were nasopharyngitis (44.4%, 42.2%, and 38.4% in the denosumab, placebo, and alendronate groups, respectively) and cystitis (5.9%, 6.0%, and 3.7%, respectively). These infections were all mild in severity. Two subjects in both the denosumab and alendronate groups experienced biochemical hypocalcemia without clinical symptoms. No cases of delayed fracture healing, ONJ, or atypical fracture of the femur were reported in any of the treatment groups. No subjects developed neutralizing antibodies to denosumab in the denosumab or placebo groups.

###### 

Summary of Adverse Events

  Adverse event                                 Double blind   Open label   
  --------------------------------------------- -------------- ------------ ------------
  All                                           448 (94.3)     446 (92.7)   229 (94.6)
  Serious                                       66 (13.9)      68 (14.1)    30 (12.4)
  Fatal                                         5 (1.1)        5 (1.0)      0 (0.0)
  Leading to study discontinuation              5 (1.1)        2 (0.4)      2 (0.8)
  Leading to discontinuation of IP              23 (4.8)       31 (6.4)     18 (7.4)
  AEs of interest                                                           
      Hypocalcemia                              2 (0.4)        0 (0.0)      2 (0.8)
      Bacterial cellulitis                      6 (1.3)        3 (0.6)      0 (0.0)
      Infection                                 286 (60.2)     269 (55.9)   131 (54.1)
      Eczema                                    70 (14.7)      81 (16.8)    31 (12.8)
      Potentially related to hypersensitivity   90 (18.9)      105 (21.8)   45 (18.6)
      Cardiovascular disorder                   68 (14.3)      63 (13.1)    21 (8.7)
      Malignant or unspecified tumors           9 (1.9)        11 (2.3)     2 (0.8)
      Fracture healing complication             0 (0.0)        0 (0.0)      0 (0.0)
      ONJ                                       0 (0.0)        0 (0.0)      0 (0.0)
      Atypical femoral fracture                 0 (0.0)        0 (0.0)      0 (0.0)
  Serious AEs of interest                                                   
      Hypocalcemia                              0 (0.0)        0 (0.0)      0 (0.0)
      Bacterial cellulitis                      0 (0.0)        0 (0.0)      0 (0.0)
      Infection                                 5 (1.1)        7 (1.5)      3 (1.2)
      Eczema                                    0 (0.0)        0 (0.0)      0 (0.0)
      Potentially related to hypersensitivity   0 (0.0)        0 (0.0)      1 (0.4)
      Cardiovascular disorder                   6 (1.3)        7 (1.5)      2 (0.8)
      Malignant or unspecified tumors           7 (1.5)        10 (2.1)     2 (0.8)

The analysis of AEs included those of all subjects who received at least one dose of IP. Reported AEs were coded by using Medical Dictionary for Regulatory Activities, version 14.0.

Discussion
==========

Denosumab 60 mg sc every 6 months for 24 months significantly decreased the risk of new or worsening vertebral fractures by 65.7% compared with placebo in Japanese subjects with osteoporosis. Subsequent post hoc sensitivity analyses showed that these results were not affected by the presence of a small number of subjects who were not classified as osteoporosis (data not shown). The reduction in the risk of vertebral fracture in postmenopausal women was significant and similar to that observed in the overall population. The incidence of new or worsening vertebral and new vertebral fracture in older men in the denosumab group was lower than that in the placebo group, although the difference in these incidences did not reach statistical significance, possibly due to the small sample size ([Figure 2](#F2){ref-type="fig"}).

The risk reduction of denosumab on vertebral fracture to placebo in Japanese women with postmenopausal osteoporosis is similar to that observed in FREEDOM, including predominantly Caucasian postmenopausal women ([@B1], [@B2]). The HR (95% CI) for new or worsening vertebral fracture (denosumab vs placebo) in postmenopausal women in DIRECT was 0.37 (0.21--0.65) at 24 months. The risk ratio (95% CI) for the new or worsening vertebral fracture (denosumab vs placebo) in postmenopausal women in FREEDOM was 0.29 (0.21--0.39) at 24 months ([@B9]). The 95% CI was narrower in FREEDOM due to the larger sample size than DIRECT, but the range of CIs of the two studies overlap considerably. Thus, the efficacy of denosumab on the relative risk reduction of vertebral fracture in postmenopausal osteoporosis is consistent between Japanese and predominantly Caucasian women.

Results of the analysis on the incidence of nonvertebral fractures were complex: the incidence of total nonvertebral fracture was similar between the denosumab and placebo groups; there was a trend for a lower incidence of major nonvertebral fracture in the denosumab group compared with the placebo group; and the incidence of nonmajor nonvertebral fracture was higher in the denosumab group compared with the placebo group. The risk of nonvertebral fracture was consistently lower in the denosumab group compared with the placebo group at 2 and 3 years in FREEDOM ([@B1]). The incidence of nonvertebral fracture in the denosumab group in DIRECT (4.1%) was apparently similar to that in FREEDOM. Therefore, the difference in the effect of denosumab on the risk of nonvertebral fracture between DIRECT and FREEDOM is unlikely due to the low incidence of nonvertebral fracture in Japanese subjects, but it may be related to the smaller sample size of DIRECT, as compared with FREEDOM.

The gains of BMD from baseline at the lumbar spine, total hip, and femoral neck in this study were comparable with those in FREEDOM and other studies ([@B1], [@B10]). In DIRECT, however, the BMD gain from baseline at the distal one third radius with denosumab was 0.5% on average at 24 months, smaller than the gains of 1.0%--2.0% on average observed in other studies. At the distal one third radius, the BMD loss in the placebo group was −1.8% on average at 24 months in DIRECT. Thus, the difference in the mean values at the distal one third radius between the denosumab and placebo groups was 2.3%, which is comparable with the gains obtained by denosumab compared with placebo in the trials of predominantly Caucasian women during the period of 2 years ([@B10]). Changes in BTMs in this study were similar to the effects of denosumab reported in previous studies in Caucasians postmenopausal women with low bone mass ([@B10]) and Japanese postmenopausal women with osteoporosis ([@B3]).

The 24-month treatment with denosumab was well tolerated. No apparent differences in the AEs of the interest were observed between the denosumab and placebo groups.

The results of the BMD and BTMs as a referential comparison for the alendronate vs denosumab or placebo group were consistent with previous studies ([@B11][@B12][@B13]). The HR for new vertebral fracture between the alendronate and placebo groups in DIRECT (0.641) was within the range of 95% CI (0.41--0.68) observed in the Fracture Intervention Trial ([@B14]). The apparent lower incidence of vertebral fracture in the denosumab group compared with the alendronate group may be related to the earlier spine BMD increase and stronger inhibition of bone resorption by denosumab but also to use of the alendronate dosage approved in Japan, which is half the dosage used in the United States. The incidence of nonmajor nonvertebral fracture was numerically higher in the denosumab group than the alendronate group. This difference may be caused by the relatively small sample size, and is unlikely to be clinically significant due to inconsistency of the results of the vertebral fracture, BMD, and BTMs. No apparent difference in the safety profile was observed between the denosumab and alendronate groups. Therefore, denosumab could be used safely in the treatment of osteoporosis for Japanese patients, as is alendronate.

This study included a relatively small number of subjects, and the study duration was only 24 months, which may have limited the ability to detect rare AEs such as hypocalcemia, bacterial cellulitis, and ONJ. The study was also underpowered to test the efficacy of denosumab on the prevention of nonvertebral and hip fracture. The interpretation of the results of the referential comparison for alendronate vs denosumab or placebo is limited by the fact that this study was not designed to assess the difference in fracture incidence between the alendronate and denosumab or placebo groups. In addition, the alendronate dosage that was used in this study, ie, 35 mg weekly, which is approved in Japan, is different from the globally approved dose of 70 mg weekly.

In conclusion, denosumab 60 mg every 6 months significantly reduced the risk of vertebral fracture in Japanese subjects with osteoporosis who had existing mild or moderate vertebral fractures. These results provide evidence for the efficacy and safety of denosumab 60 mg sc every 6 months in the treatment of Japanese subjects with osteoporosis.
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